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Abstract
Introduction: The 90-90-90 targets set by the United Nations aspire to 73% of people living with HIV (PLHIV) being virally
suppressed by 2020. Using the HIV Synthesis Model, we aim to mimic the epidemic in Zimbabwe and make projections to
assess whether Zimbabwe is on track to meet the 90-90-90 targets and assess whether recently proposed UNAIDS HIV tran-
sition metrics are likely to be met.
Methods: We used an approximate Bayesian computation approach to identify model parameter values which result in model
outputs consistent with observed data, evaluated using a calibration score. These parameter values were then used to make
projections to 2020 to compare with the 90-90-90 targets and other key indicators. We also calculated HIV transition metrics
proposed by UNAIDS (percentage reduction in new HIV infections and AIDS-related mortality from 2010 to 2020, absolute
rate of new infections and AIDS-related mortality, incidence–mortality ratio and incidence–prevalence ratios).
Results: After calibration, there was general agreement between modelled and observed data. The median predicted out-
comes in 2020 were: proportion of PLHIV (aged 15 to 65) diagnosed 0.91 (90% uncertainty range 0.87, 0.94) (0.84 men,
0.95 women); of those diagnosed, proportion on treatment 0.92 (0.90, 0.93); of those receiving treatment, proportion with
viral suppression 0.86 (0.81, 0.91). This results in 72% of PLHIV having viral suppression in 2020. We estimated a per-
centage reduction of 36.5% (13.7% increase to 67.4% reduction) in new infections from 2010 to 2020, and of 30.4%
(9.7% increase to 56.6% reduction) in AIDS-related mortality (UNAIDS target 75%). The modelled absolute rates of HIV
incidence and AIDS-related mortality in 2020 were 5.48 (2.26, 9.24) and 1.93 (1.31, 2.71) per 1000 person-years respec-
tively. The modelled incidence–mortality ratio and incidence–prevalence ratios in 2020 were 1.05 (0.46, 1.66) and 0.009
(0.004, 0.013) respectively.
Conclusions: Our model was able to produce outputs that are simultaneously consistent with an array of observed data and pre-
dicted that while the 90-90-90 targets are within reach in Zimbabwe, increased efforts are required in diagnosing men in particular.
Calculation of the HIV transition metrics suggest increased efforts are needed to bring the HIV epidemic under control.
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1 | INTRODUCTION
In 2014, the United Nations Programme on HIV and AIDS
introduced the 90-90-90 targets by 2020, 90% of people living
with HIV (PLHIV) will be diagnosed, of those diagnosed 90% of
people will be receiving antiretroviral treatment and among
those receiving treatment, 90% will be virally suppressed [1].
While it is arguable whether the 90-90-90 targets should be a
primary target for a healthcare system, in so far as they do not
distort rational resource allocation between healthcare options
in countries, such targets can have a galvanizing effect and
much progress has been made to meet them. However, there
is still room for further advancement. In Zimbabwe, a 2016
population-based survey (Zimbabwe Population-Based HIV
Impact Assessment (ZIMPHIA)) suggests that a quarter of
PLHIV were not aware of their HIV status in 2016 [2],
although there is likely to be some under-reporting of HIV
diagnosis [3]. Of those reporting having been diagnosed, 86.8%
self-reported use of antiretroviral therapy (ART) and, among
these people, 86.5% had viral suppression [2]. The 90-90-90
target amounts to 73% of PLHIV achieving viral suppression by
2020. In ZIMPHIA, the corresponding estimate was 60.4% [2].
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Prevalence rates (henceforth referred to as ‘prevalence’)
and incidence estimates are crucial to understand the current
status of the HIV epidemic and, in particular, to identify
whether trends suggest an improving epidemic, as was
intended to be achieved by the 2020 Joint United Nations
Programme on HIV/AIDS (UNAIDS) targets. Estimates from
UNAIDS suggests that adult HIV prevalence and HIV inci-
dence in Zimbabwe have decreased considerably since 1998
[4], although for HIV prevalence, the level now appears to be
stable at around 14% in 2016, as reported by nationally rep-
resentative surveys (DHS 2015/6 (13.8%), ZIMPHIA 2016
(14.0%)) [2, 5]. Estimates based on the Spectrum model also
suggest that HIV incidence has continued to fall since 1998
[4] and, in 2017, the ZIMPHIA reported an HIV incidence of
0.45 per 100 person-years among 15 to 64 year olds.
A recent report has outlined HIV transition metrics which
can be considered in defining “epidemic control” and therefore
aid understanding of the current HIV epidemic [6]. It would
be useful to see the results of these measures in the context
of Zimbabwe, in order to have a more robust understanding
of the current epidemic.
Using the HIV Synthesis Model [7], we here aim to mimic
the epidemic in Zimbabwe and compare outputs from this
individual-based model to a range of observed data and
describe recent trends in the HIV epidemic. We also project
future trends in key indicators to 2020 with the aim of
assessing whether Zimbabwe is on track to meet the 90-90-
90 targets by 2020. Finally, we calculate the HIV transition
metrics to assess the extent to which they appear to be con-
sistent with the 90-90-90 targets.
2 | METHODS
We used an individual-based model of HIV transmission,
progression and the effect of ART in the adult population in
Zimbabwe which has been previously described [7]. In brief,
each time the model programme is run it simulates values of
variables for the number of short-term condomless sex part-
ners, the presence of a long-term condomless sex partner,
HIV testing, HIV acquisition and, additionally, in PLHIV, viral
load, CD4 count, use of specific ART drugs, adherence to
ART, resistance to specific drugs and risk of HIV-related
death, each updated in three-month time steps from 1989.
For the purposes of this paper, the model was calibrated to
data from Zimbabwe. An approximate Bayesian computation
[8] approach was used; this involves sampling model parame-
ter values from various possible values, represented by prior
distributions (see Data S2, Table 1) and assessing how closely
the model outputs concur with observed data on the real-life
HIV epidemic and ART programme in Zimbabwe. Observed
data were obtained from: ZIMPHIA [2], DHS [5], Global AIDS
Response Progress Reports [9], WHO Resistance Report [10],
Zimbabwe Ministry of Health [11,12], published papers
[13,14] and UN Reports [15].
2.1 | Calibration score
Our approach was to derive a calibration score that conveys
the average proportionate deviance of the modelled outputs
from the observed data over a range of data items. Details of
the calibration, including the number of data items included in
the original calibration score are given in Data S2.
The aim of the calibration process was to find 500 parame-
ter sets that yielded an overall calibration score of <0.30.
Model outputs for all items included in the score and other
outputs of interest were compared with observed data for
runs in which the score was <0.3.
In the second phase of the analyses, we made projections
to 2020 to describe trends in prevalence, incidence, propor-
tion diagnosed, proportion on treatment, proportion virally
suppressed and proportion with resistance. Trends in the num-
ber of PLHIV, number of new infections per years, number of
new diagnoses per year and number of AIDS deaths per year
were also described. We reported medians and 90% ranges,
calculated by taking the 10th and 90th centile across the
range of runs used. To make these projections, each time the
model was run one of the 500 parameter sets that had a cali-
bration score below 0.30 was selected at random and used to
replace the original random probability distributions for these
model parameters. Each parameter set had an equal probabil-
ity of being chosen. We ran the model 1500 times and again
only selected runs for which the calibration score was <0.3.
This latter criterion was not fulfilled for all runs, despite using
the 500 selected parameter sets due to stochastic variation.
We considered three alternative methods of calculating the
calibration score. This was to explore the implications of
favouring different data items within the score; the rationale
for each alternative score is described in Data S3. When
describing the trends between 2017 and 2020, we assumed
no change in national ART regimens and a constant rate of
testing (which entailed 20% men and 30% women tested in
the last year in 2017 (see Data S2: Description of Model Cali-
bration, page 32)). We also assumed all people were eligible
for ART at HIV diagnosis during this time, as per current
guidelines [16]. Finally, we assumed that eligibility for, and rate
of, circumcision remained unchanged (all men aged 15 to 49
were eligible for circumcision determined by age-specific prob-
ability of being circumcised, if not previously diagnosed with
HIV). Details of specific rates can be found in Data S1 (Mate-
rial: Calibration to Zimbabwe, Interventions and populations,
page 43). We do not explicitly model transactional sex within
the model. However, we hypothesize that both the number
and epidemic trends among women with greater than three
condomless sex partners in the model will be similar to the
number and epidemic trends among women engaged in sex
work in Zimbabwe. We are aware of the complexities in
explicitly modelling sex work but feel our approach allows a
useful comparison between modelled phenomena and
observed data.
Finally, we calculated the percentage reduction in new HIV
infections and AIDS-related mortality from 2010 to 2020, the
absolute rate of new infections and AIDS-related mortality,
the incidence–mortality ratio and incidence–prevalence ratios.
These outputs were compared to the thresholds in the
recently published UNAIDS document [6] focussing on defin-
ing HIV transition metrics which can be used to consider
whether the HIV epidemic is under control. In addition, we
calculated four other outputs of interest: total number of
adults living with HIV; total number of new infections per
year; total number of new diagnoses per year; and the total
number of AIDS-related deaths per year.
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3 | RESULTS
Of the 500 runs that had a c-score of <0.3, the median
c-score was 0.27 (90% range: 0.22, 0.29).
Comparison of the modelled data items using the original
score with the latest available observed data is shown in
Table 1. The modelled estimates for incidence of HIV
(median over 500 runs: 0.50/100 person-years (90% range:
0.20, 0.96) for men and 0.76/100 person-years (0.27, 1.53)
for women) and proportion of HIV-positive people diagnosed
(0.77 (90% range: 0.70, 0.84) for men and 0.92 (0.87, 0.96)
for women) were higher than the observed data (0.28/100
person-years for men, 0.67/100 person-years for women
and 0.70 for men and 0.77 for women respectively [2]).
However, these modelled values were a result of a good fit
of all other items in the score and the extent to which the
observed data are underestimates is unclear. The modelled
estimate for number of female sex workers (FSWs) was also
higher than the observed data, though the observed data
did fall within the 90% modelled range. Table 1 also shows
selected comparisons between other data items of interest
and, in particular, the proportion with viral suppression of
those on ART. Again, there is a good concordance between
observed data and model outputs; 84% of males have viral
load suppression while on ART according to the ZIMPHIA
survey, compared to 88% in our model outputs and the
respective proportions for females are 88% (observed) and
86% (modelled). Further comparisons with a broad range of
data items are given in the Description of Model Calibration
document.
Table 1. Comparison of latest available observed and modelled data for components of the original c-score
Components included in the original calibration
score
Observed data
Modelled estimate across runs
Median (90% range)Source
Year of
comparison Estimate (95% CI) %
Prevalence – men 15 to 49 ZIMPHIA [2] 2016.25 0.11 (0.10, 0.12) 0.10 (0.08, 0.13)
Prevalence – women 15 to 49 ZIMPHIA [2] 2016.25 0.17 (0.16, 0.17) 0.16 (0.13, 0.21)
Prevalence – men 15 to 24 DHS [5] 2015.75 0.03 0.02 (0.01, 0.04)
Prevalence – women 15 to 24 DHS [5] 2015.75 0.07 0.05 (0.02, 0.08)
Prevalence – FSWs 15 to 65 Cowan 2017 [13] 2013.75 0.58 (0.43, 0.79) 0.47 (0.26, 0.72)
Incidence per 100 person-years – men 15 to 49 ZIMPHIA [2] 2016.25 0.28 (0.06, 0.50) 0.50 (0.20, 0.96)
Incidence per 100 person-years – women 15 to 49 ZIMPHIA [2] 2016.25 0.67 (0.37, 0.97) 0.76 (0.27, 1.53)
Number of HIV tests – all 15 to 49 GARCPR [9] 2016.5 22,01,246 23,59,360 (17,06,740, 30,28,040)
Proportion diagnosed of those with HIV – men 15
to 64
ZIMPHIA [2] 2016.25 0.697 0.77 (0.70, 0.84)
Proportion diagnosed of those with HIV – women
15 to 64
ZIMPHIA [2] 2016.25 0.771 0.92 (0.87, 0.96)
Number on ART3 – men 15 to 64 MoH [11] 2015.75 3,01,650 2,70,100 (2,09,875, 3,38,720)
Number on ART3 – women 15 to 64 MoH [11] 2015.75 5,16,557 5,23,775 (4,08,435, 6,44,590)
Number on 2nd line – all 15 to 64 MoH [12] 2014.75 12,696 14,965 (0, 36,135)
Proportion suppressed of those with HIV – men 15
to 64
ZIMPHIA [2] 2016.25 0.53 (0.51, 0.58) 0.57 (0.48, 0.64)
Proportion suppressed of those with HIV – women
15 to 64
ZIMPHIA [2] 2016.25 0.64 (0.62, 0.67) 0.67 (0.60, 0.71)
Proportion with resistance at ART initiation – all 15
to 64
WHO Resistance
reporta,b [10]
2010.5 0.09 (0.03, 0.22) 0.04 (0, 0.10)
Number of FSW 18 to 49 Cowan[14] 2017.25 73,270b 1,27,385 (60,225, 2,00,020)
Number of pregnancies 15 to 49 UN [15] 2013.5 3,98,474 4,58,440 (2,10,240, 7,65,040)
Other variables of interest
Proportion suppressed of those on ART – men
15 to 64
ZIMPHIA [2] 2016.25 0.84 0.88 (0.80, 0.94)
Proportion suppressed of those on ART – women
15 to 64
ZIMPHIA [2] 2016.25 0.88 0.86 (0.81, 0.92)
Proportion with resistance at ART initiation – all
15 to 64
WHO Resistance
report [28]
2016.5 0.11 (0.07, 0.16) 0.07 (0, 0.18)
Number of circumcisions per year GARCPR [9] 2015.5 1,06,286 1,16,800 (89,060, 1,44,540)
ART, antiretroviral therapy; FSW, female sex workers; ZIMPHIA, Zimbabwe Population-Based HIV Impact Assessment.
aWHO Resistance Report 2017 was published after completion of the calibration process hence was not included in the calibration score; bsee
“Description of Model Calibration” document for FSW calculation.
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In the second phase of the analyses, we projected forward
to 2020 and analysed results at 2017 and at 2020 (Figure 1).
We predict little change in the prevalence of HIV from 2017
to 2020, though predict incidence to fall by a mean of 0.06/
100 person-years, albeit with substantial uncertainty in this
trend (90% range: 0.16, 0.03). With continuation of current
testing rates, the overall predicted proportion of PLHIV diag-
nosed by 2020 is estimated to be 0.91 (90% range: 0.87,
0.94). We predict a mean 0.05 absolute increase (90% range:
0.02, 0.07) in the proportion of men diagnosed and a 0.02
absolute increase (90% range: 0.00, 0.04) in the proportion of
women diagnosed, resulting in an overall proportion of 0.84
(90% range: 0.78, 0.90) of men diagnosed with HIV and 0.95
(90% range: 0.91, 0.97) of women diagnosed in 2020. The
proportion of HIV-positive people diagnosed with HIV receiv-
ing ART is expected to increase by 0.02 (90% range: 0.01,
0.06), resulting in 0.92 (90% range: 0.90, 0.93) of diagnosed
people on treatment in 2020. Of those receiving ART, there is
minimal predicted change in the proportion of people with viral
suppression. The overall proportion of people with viral sup-
pression in 2020 is predicted to be 0.86 (90% range: 0.81,
0.91); 0.87 (90% range: 0.78, 0.92) of men and 0.86 (90%
range: 0.82, 0.91) of women had viral load suppression in
2020. Of those aged 15 to 49 living with HIV (undiagnosed as
well as diagnosed), 0.37 (90% range: 0.31, 0.43) had unsup-
pressed viral load in 2017, compared to a predicted 0.30 (90%
range: 0.25, 0.36) in 2020. The proportion of people with
non-nucleoside reverse transcriptase inhibitors (NNRTI) resis-
tance at time of starting ART is expected to increase markedly
in three years time, from 0.05 (90% range: 0.01, 0.13) in 2017
to 0.13 (90% range: 0.05, 0.23) in 2020; a change of 0.07
(0.01, 0.16). Modelled estimates in 2017 and in 2020 using
the three alternative calculations were in line with those calcu-
lated using the original score and are shown in Data S3.
There was little difference in the projected number of
PLHIV: 1,130,770 (90% range: 881,840, 1,394,665) in 2017
and 1,130,305 (90% range: 875,303, 1,431,397) in 2020; or
the number of new infections per year: 41,610 (90% range:
18,615, 67,890) in 2017 and 40,515 (90% range: 17,155,
66,795) in 2020. The number of new diagnoses per year was
58,400 (90% range: 32,120, 90,520) in 2017 and 43,800
(90% range: 22,165, 70,611) in 2020. The number of AIDS-
related deaths per year was similar (17,520 (90% range:
8760, 29,200) in 2017 and (18,051 (90% range: 11,680,
25,882); change of 0 (95% range: 8893, 78310).
Finally, we calculated a modelled percentage reduction in
new infections from 2010 to 2020 of 36.5% (90% range:
13.7% increase to 67.4% reduction), and in AIDS-related mor-
tality of 30.4% (90% range: 9.7% increase to 56.6% reduction.
The interim impact target for both these measures agreed by
the United Nations Assembly was a 75% reduction. The abso-
lute rates of modelled incidence and AIDS-related mortality in
2020 were 5.48 (90% range: 2.26, 9.24) and 1.93 (1.31, 2.71)
per 1000 person-years respectively. The modelled incidence–
mortality ratio and incidence–prevalence ratios in 2020 were
1.05 (90% range: 0.46, 1.66) and 0.009 (90% range: 0.004,
0.013) respectively.
4 | DISCUSSION
Using an individual-based model and a range of observed data
in Zimbabwe, we were able to mimic the current HIV epidemic
and project future trends in key indicators, including the 90-90-
90 targets. The UNAIDS 90-90-90 targets in 2020 are within
reach according to our projected trends, given increased efforts
in diagnosing men in particular. While we predict 90.7% of
adults with HIV overall will be diagnosed in 2020, the respec-
tive estimates for men and women are 84% and 95%. We esti-
mate that 92% of people diagnosed will be receiving treatment,
and of these, 86% will be virally suppressed (although may
potentially be biased due to people under-reporting treatment).
Ninety per cent is within our uncertainty range; and continued
commitment to the Extended Zimbabwe National HIV and
AIDS Strategic Plan [17] may increase this estimate further.
The United Nations Assembly have suggested a target of a
75% reduction in new infections and AIDS-related deaths
between 2010 and 2020. In Zimbabwe, the percentage reduc-
tion for both these modelled outputs was <30%, with wide
variability around the estimates suggesting that we cannot
rule out a percentage increase. While this transition metric
does not take into account the achievements made prior to
2010, it does suggest that there is still considerable work to
be done to reduce the number of new infections and AIDS-
related deaths. The modelled absolute rates of HIV incidence
and AIDS-related deaths in 2020 were both above 1/1000
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Figure 1. Median (90% range) modelled projections at 2017 and 2020.
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person-years. Rates below 1/1000 person-years have been
used to define elimination of HIV [18], and UNAIDS have also
suggested that rates below 1/1000 person-years could be rel-
evant in higher incident and prevalence settings [6]. Potential
issues with our projected incidence measure are discussed
later in this section and so though it is considerably higher
than 1/1000 person-years our model may not reflect the true
incidence. Our modelled incidence–mortality ratio was 1.05.
UNAIDS do state a benchmark of one for this transition
metric; however, this is only relevant with a measure of low
mortality among PLHIV or high ART coverage, defined as
>81% of PLHIV (P Ghys, personal communication). Zimbabwe,
according to the ZIMPHIA estimates, does not currently meet
the 81% ART coverage. However, using estimates from our
model, we predict 84% ART coverage and in this case, the
incidence–mortality ratio implies that there are more new
infections than deaths per year. Hence, it is likely that, despite
the reduction in prevalence, the number of PLHIV is on the
rise, due to population growth. The modelled incidence–preva-
lence ratio takes into account duration of life after HIV acqui-
sition. Our projected output was below the target suggested,
of 0.03, based on an average survival of people with HIV of
33 years after acquisition. This transition metric suggests that
the total number of PLHIV will eventually fall, and hence, the
epidemic is in a “state of control.” This interpretation is not in
line with the interpretation of the three metrics prior to this
(percentage reduction in new infections/AIDS-related deaths,
the absolute rates of new infections/AIDS-related mortality
and the incidence–mortality ratio) which suggest that
increased efforts are needed to bring the HIV epidemic under
control. This also suggests that even if the 90-90-90 targets
were achieved, the HIV transition metrics are unlikely to all
be met, and hence, there may be a lack of consistency
between the two sets of targets, certainly in the short term.
Our modelled estimate of prevalence of HIV in women who
had greater than three condomless sex partners in the past
three month period was lower than observed data among
FSWs [13]. This may be due to differences in the make-up of
these two groups: for example, our modelled estimate for the
number of FSWs was markedly higher than the empirical esti-
mate on the number of FSWs, which itself is difficult to accu-
rately estimate. To reflect this uncertainty, we allowed
substantial variability over model runs in sexual behaviour
parameter values which determine the number of women with
greater than three condomless sex partners within the model.
When projecting forward to 2020 using the original calibra-
tion score, HIV incidence was projected to drop by 0.06 per
100 person-years. Given the uncertainty around the incidence
estimate, the degree of decrease is difficult to accurately quan-
tify. We project that by 2020, the proportion of people diag-
nosed with HIV will increase, particularly in men, assuming the
rate of testing remains at the current level. This may be due to
a lower proportion of men diagnosed in 2017 compared
to women, and hence, there is more scope for this estimate to
increase. It is hoped that these estimates may increase even
further, in line with increased efforts in testing for HIV in men,
within for example the circumcision programme currently
underway in Zimbabwe [19] and with the planned rollout of
HIV self-testing which is likely to attract a significant propor-
tion of men (TA, Zimbabwe MoH, personal communication).
The proportion of people with NNRTI resistance at ART
initiation is also projected to increase by 9% to an overall 15%
by 2020. This is of particular concern in this setting, given the
limited access and availability of alternative first line regimens.
Adherence counselling and efforts to increase testing have,
and are currently taking place but continued effort in these
areas is needed to ensure transmitted drug resistance does
not become an issue that is unable to be effectively addressed.
WHO guidelines have changed the national first line ART regi-
men in new initiators to be dolutegravir, rather than efavirenz,
containing in countries with pre-ART NNRTI resistance >10%
[20], and it is predicted this change would be both effective
and cost-effective [21]. The Zimbabwe treatment guidelines
have not yet incorporated this change [16]. Recent data sug-
gesting a potential risk of neural tube defects in women who
are on dolutegravir at the time of conception create doubt
over the timing and nature of dolutegravir introduction [22].
Generally, the estimates obtained using the alternative cali-
bration scores are in line with our original calibration score,
suggesting that the weights and data items used in our origi-
nal score are robust. This implies that if the assumptions hold
(in terms of testing, number of circumcisions, number of peo-
ple receiving treatment, etc.) our projections to 2020 are
likely to be in line with observed data in the future or may
even be an underestimation of the potential benefits, particu-
larly since there are ongoing efforts to improve the status of
the HIV epidemic in Zimbabwe.
When comparing observed and modelled outputs, we found
a good fit across the majority of components included in the
score. We did however see a higher predicted HIV incidence
(within the 95% observed CI for women but not for men) and
a higher predicted proportion diagnosed compared to those
reported in ZIMPHIA. There is particular uncertainty over the
current incidence since the only data source to inform this is
the recent ZIMPHIA estimate [2], which was calculated using
the recent infection algorithm [23]. There are concerns of
using a single method to estimate incidence [24]; hence, the
ZIMPHIA estimate should be interpreted with caution. In con-
trast, the prevalence estimates are informed by three DHS
surveys as well as ZIMPHIA [5,25,26], and we did indeed see
a good fit when comparing our modelled prevalence data to
observed data. Our estimate for proportion of PLHIV who
have been diagnosed is higher than that seen in ZIMPHIA [2],
which was the only data source available for this item. Our
modelled estimate was a result of a good agreement of all
other components of the score. Furthermore, the results from
ZIMPHIA on HIV status are based on self-reported data and
hence must be interpreted with caution. It is highly likely that
not all people diagnosed with HIV report as having been diag-
nosed when asked; this has been demonstrated in other sur-
veys [3] and if this is the case, it would result in an
underestimation in the proportion diagnosed.
5 | CONCLUSIONS
It is essential to have reliable observed data in order to cali-
brate models well to specific settings and hence accurately
replicate past trends in order to predict future trends. While
our score proved to be robust, there are some data items that
are both difficult to model and obtain reliable data on. Surveys
like the DHS and ZIMPHIA are invaluable in terms of the
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information they provide and are a good indication of whether
treatment programmes are working. However, it is likely that
some of the outputs reported in these surveys, for example,
the proportion of people diagnosed with HIV, and the propor-
tion of people receiving treatment are underestimated due to
stigma surrounding a HIV diagnosis and hence failure to dis-
close status. Further data collection, perhaps in the form of
complete healthcare provider records, together with commit-
ment to the Monitoring and Evaluation Plan as outlined in the
National Strategic Plan [17] would be necessary to fully under-
stand the impact of HIV in Zimbabwe and work towards
achieving and surpassing the 90-90-90 UNAIDS target. Con-
siderable efforts are needed to reach the benchmarks sug-
gested by the UN when calculating the HIV transition metrics,
and in particular, to achieve the recommended 75% reduction
in the number of new HIV infections. It is important to recog-
nize that while continued efforts in testing are likely to reduce
the number of people with undiagnosed HIV, the proportion of
these people that are hard to reach is likely to increase and
hence increased resources may be required for outreach
testing to maintain current testing rates. Furthermore, while
continued efforts are needed to diagnose and treat those
with HIV, resources also need to be used to maximize preven-
tion of HIV [27], provided that the use of such resources is
cost-effective.
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